Oyvind Steinsbo
Bergen, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.
Journal: Scandinavian journal of gastroenterology
Published: October 17, 2025
Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy.
Journal: Scandinavian journal of immunology
Published: March 28, 2025
Fecal Calprotectin Correlates With Disease Extent but Remains a Reliable Marker of Mucosal Healing in Ulcerative Colitis.
Journal: The American journal of gastroenterology
Published: October 30, 2024
Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis.
Journal: Therapeutic advances in gastroenterology
Published: July 22, 2022
Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: March 21, 2019
Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell Origins.
Journal: Cell reports
Published: May 19, 2017
Stereotyped antibody responses target posttranslationally modified gluten in celiac disease.
Journal: JCI insight
Published: March 13, 2017
Gluten-specific antibodies of celiac disease gut plasma cells recognize long proteolytic fragments that typically harbor T-cell epitopes.
Journal: Scientific reports
Published: October 19, 2015
Small bowel, celiac disease and adaptive immunity.
Journal: Digestive diseases (Basel, Switzerland)
Published: May 01, 2015
Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells.
Journal: Nature communications
Published: January 03, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026